

Schriftenreihe zur Gesundheitsanalyse – Band 42

BARMER

Arzneimittelreport 2023

Medikamentöse Schmerztherapie nicht-onkologischer
ambulanter Patientinnen und Patienten

Daniel Grardt, Veronika Lippke
und Ingrid Schubert

WIP Wissenschaftliches
Institut für
Pharmazie

Christian O. Jacke | Frank Wild

**Arzneimittel-
versorgung von
Privatversicherten
2023**

Pharmazie, Analysen, PKV-GKV-Vergleich

Medizinisch Wissenschaftliche Verlagsgesellschaft



Wolf-Dieter Ludwig · Bernd Mühlbauer
Roland Seifert *Hrsg.*

**Arzneiverordnungs-
Report 2023**

Springer

AMNOG-REPORT

Das Arzneimittel-Preisermittlungs-
verfahren des BfArM



BAK
Bundesärztekammer
Deutschland



GKV-Arzneimittel-Schnellinformation
für Deutschland
nach § 94 Abs. 3 SGB V

Stand: 1. September 2023
Konsolidierte Fassung
Ausschuss Sachverständigen

Prescription Reports in Germany

PPRI Network Meeting, Vienna
24.04.2024
Dr. Melanie Schröder

Agenda

- ▶ prescription reports: why and how?
- ▶ variety of reports

Once upon a time...

- ▶ “[...] trend in expenditures gives increasing cause for concern”
- ▶ “[...] for many years, drug consumption in the Federal Republic of Germany was a well-kept secret of the pharmaceutical industry. A research project, the current results of which have been compiled in the Arzneiverordnungs-Report 1985, is clearing up this situation.” (Schwabe & Paffrath, 1985)
- ▶ based on prescriptions by statutory health insurance (SHI): starting from a 1% random sample to full census since 2002
- ▶ focus is/was transparency
- ▶ became famous in 1997 → legal action against publisher due to discussion on “controversial” drug groups



Structure and information

- ▶ Section 1: Economics & Statistics
 - Total pharmaceutical expenditures and consumption
 - ▶ Development over time (since 1984)
 - ▶ Subgroups (patented drugs, generics, orphans, biologicals, biosimilars, AMNOG...)
 - International price comparison: patented drugs (latest 2018)
 - Other: confidential discount agreements (aggregated data), biosimilars, gene therapies
- ▶ Section 2: Developments within pharmaceutical/disease groups
 - Arterial hypertension, ..., ..., Vitamins and minerals (35 chapters)

96 health insurances → variety of reports (1)

▶ Arzneimittel-Kompass 2022 (AOK Research Institute – WIdO)

- different focus, i.e. high priced medicines (2021)
- subgroups (patented drugs, generics, orphans, biologicals, biosimilars, AMNOG...)
- decomposition of expenditure increase (y2y) to explain the causes (price, volume, structure)
- AMNOG: Analyses of the results of the benefit assessments of the G-BA (HTA)
- and price negotiations → prices are transparent

74M

▶ AMNOG-Report 2023 (DAK-Gesundheit)

- main focus AMNOG → current questions (legislative changes, orphan drugs)
- use own data and extrapolate to SHI population

5M

74M

96 public health insurances → variety of reports (2)

- ▶ Gesundheitsreport – Arzneiverordnungen 2023 (Techniker Krankenkasse)
 - Subgroups due to patients' age, sex, region, occupation, education and ATC-groups
- ▶ Barmer Arzneimittelreport 2023 (BARMER Institute for Health Systems Research – bifg)
 - focus patient care: treatment with painkillers without cancer diagnosis, polypharmacy, medication during pregnancy
- ▶ Arzneimittelversorgung von Privatversicherten (Scientific Institute of Private Health Insurance – WIP)
 - Subgroups (patented drugs, generics, orphans, biologicals, biosimilars, AMNOG...)
 - differences between SHI and private (expenditures, share of generics, ...)

11M

9M

8M

Conclusion

- ▶ Report → publications that appear regularly, usually annually (SHI-focus)
- ▶ Long history of prescription reports in Germany (SHI)
- ▶ (Most of them) same data: outpatient care
→ less information on pharmaceutical consumption in hospitals
- ▶ Aggregated data (product, active substance, no packs)
- ▶ Different focus



Thank you for your attention.



Dr. Melanie Schröder

Melanie.schroeder@gkv-spitzenverband.de



Links

- ▶ [Arzneiverordnungs-Report 2023 | SpringerLink](#) 
- ▶ [Arzneimittel-Kompass 2021: Hochpreisige Arzneimittel – Herausforderung und Perspektiven | SpringerLink](#) 
- ▶ [Arzneimittelreport 2023 \(tk.de\)](#) 
- ▶ [Arzneimittelreporte | BARMER](#) 
- ▶ [Detail | WIP: Wissenschaftliches Institut der PKV \(wip-pkv.de\)](#) 
- ▶ [amnog-report-2023-studie.pdf \(dak.de\)](#) 
- ▶ [Arzneimittel-Atlas](#) 
- ▶ [BPI – Partner im Gesundheitswesen:AMNOG-Daten](#) 
- ▶ [Berichte zum Quartalsende – GKV-GAmSi](#) 